Amylyx Pharmaceuticals Says Pivotal Phase 3 LUCIDITY Will Evaluate FDA-Agreed Upon Primary Outcome Of Reduction In Hypoglycemia Events And Designed To Align As Closely As Possible With Previous Phase 2 Trial Designs
Amylyx Pharmaceuticals Says Pivotal Phase 3 LUCIDITY Will Evaluate FDA-Agreed Upon Primary Outcome Of Reduction In Hypoglycemia Events And Designed To Align As Closely As Possible With Previous Phase 2 Trial Designs
Amylyx制药公司表示，关键的3期LUCIDITY试验将评估与FDA达成一致的主要结果，即降低低血糖事件，并旨在与之前的2期试验设计尽可能接近。
Amylyx Pharmaceuticals Says Pivotal Phase 3 LUCIDITY Will Evaluate FDA-Agreed Upon Primary Outcome Of Reduction In Hypoglycemia Events And Designed To Align As Closely As Possible With Previous Phase 2 Trial Designs
Amylyx制药表示，关键的第3期LUCIDITY将评估FDA协议的主要结局，即低血糖事件的减少，并旨在尽可能与先前第2期试验设计保持一致。
资讯热榜
更新时间